The weakness in the equity trading will continue to hurt the earnings of Morgan Stanley (NYSE: MS) for the third quarter of 2019, which has been set for Thursday before the market opens. The results could also be pressurized by low-interest rates and the two Federal Reserve rate cuts.
The market experts fear the economy slipping into recession and the Fed is trying to lower these chances by two rate cuts during the third quarter. The trading activities, which could have a relatively high impact on the results, remained sluggish due to the corporate lending slowdown and trade war concerns.
The company has been struggling to achieve revenue growth in the past three successive quarters. Investors believe Morgan Stanley could continue to fall due to possible unstable capital markets in the second half and interest rate headwinds.
Morgan Stanley is expected to face additional costs, margins pressure, and an unstable loan portfolio. The retail investors are likely to continue being cautious given record market level, short intra-quarter market swings, and heightened levels of uncertainty.
Analysts expect the company’s earnings to decrease by 5.10% to $1.11 per share and revenue to decline by 2.40% to $9.63 billion for the third quarter. The company has surprised investors by beating analysts’ expectations thrice in the past four quarters. The company’s earnings estimates were revised downward several times in recent weeks.
For the second quarter, Morgan Stanley reported a 10% drop in earnings due to continued weakness in the equity trading business. The top line declined by 3% as a sharp fall in bond and equity trading at institutional securities offset the modest growth in investment banking and wealth management segments.
The company’s peers Citigroup (NYSE: C), JP Morgan (NYSE: JPM), and Wells Fargo (NYSE: WFC) will be publishing results for their most recent quarter on Tuesday while Bank of America (NYSE: BAC) is set to release its third-quarter report on Wednesday.
Listen to on-demand earnings calls and hear how management responds to analysts’ questions
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
